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Abstract: Leishmaniasis is a disease complex caused by 20 species of protozoan parasites
belonging to the genus  Leishmania  . In humans the it has two main clinical forms,
visceral leishmaniasis (VL) and cutaneous or tegumentary leishmaniasis (CL), as well
as several other cutaneous manifestations in a minority of cases. In the mammalian
host  Leishmania  infect different populations of macrophages where they multiply and
survive in the phagolysosomal compartment. The progression of both VL and CL
depends on the maintenance of a parasite-specific immunosuppressive state based
upon this host macrophage infection. The complexity and variation of immune
responses and immunopathology in humans and the different host interactions of the
different  Leishmania  species has an impact upon the effectiveness of vaccines,
diagnostics and drugs.
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1. Introduction 
Leishmaniasis is a disease complex with two main clinical presentations – visceral leishmaniasis (VL, 
or kala-azar) and cutaneous leishmaniasis (CL). Both VL and CL have a worldwide distribution in 
nearly 100 endemic countries. Overall the number of potentially fatal VL cases has decreased during 
the past decade with an estimated annual incidence of less than 50,000 (2017 figures, 
https://www.who.int/leishmaniasis/burden/en accessed 01.10.19) with seven countries: Brazil, 
Ethiopia, India, Kenya, Somalia, South Sudan and Sudan having the major burden. The decrease in VL 
case numbers in the Indian subcontinent (ISC) is coincident with the introduction of a regional 
elimination programme launched in 2005, with improved access to diagnosis and treatment. The 
naturally cyclical pattern of transmission intensity of this anthroponotic disease may also contribute to 
this decrease in the ISC. In contrast, the number of cases in East Africa has not fallen and this endemic 
area is now a major focus for control programmes. The estimated worldwide annual incidence of CL is 
between 0.7 to 1.2 million cases [1] with Central and South America, the Middle East, Ethiopia and 
North Africa being the major endemic areas. Far less attention has been paid to the control and treatment 
of CL, a predominantly zoonotic and a slow self-curing disease (3 – 18 months in most cases) with 
disfigurement and stigma being the main corollaries of infection. In addition, there are rarer variants of 
CL: mucocutaneous leishmaniasis (MCL), diffuse cutaneous leishmaniasis (DCL), disseminated 
cutaneous leishmaniasis (DsCL), leishmaniasis recidivans (LR) and post-kala-azar dermal 
leishmaniasis (PKDL). With CL, these variant skin manifestations are often referred to collectively as 
the tegumentary leishmaniases (TL).  PKDL is a perplexing clinical presentation which follows cure of 
VL (5-10.% cases in Asia, up to 50% cases in East Africa, [2,3]).  
 
The protozoan parasites that cause VL and TL belong to at least 20 distinct species of the genus 
Leishmania (with new species being identified in the past decade) that are transmitted between 
mammalian hosts by female phlebotomine sandflies. Different species of Leishmania are largely 
responsible for the diverse clinical manifestations (Table 1) which are generated by the interplay 
between the parasite, host factors and vector biology. However, clinical cases reports suggest these 
species-dependent clinical outcomes are not distinct.  In the sand fly gut Leishmania parasites exist as 
flagellated promastigote forms, while in the mammalian host the parasites invade macrophages losing 
their flagellum and transforming into to the intracellular amastigote. The amastigote multiplies and 
survives in the phagolysosomal compartment of the macrophage.  It has long been known that 
promastigotes differentiate within the sandfly to generate infective “metacyclic” forms [4-6]  and recent 
evidence suggests that there may also be heterogeneity in the intracellular amastigote form [7-9]. 
Leishmania parasites actively manipulate both of their hosts. In the sandfly, transmission efficiency of 
metacyclic promastigotes is enhanced by secretion of a proteophosphoglycan-rich, mucin-like gel 
(Promastigote Secretory Gel, PSG), which accumulates in the sand fly gut and mouthparts [10].  
Mammalian infection is established in the skin following the inoculation of metacyclic promastigotes 
that possess a lipophosphoglycan coat that enables them to resist complement and attach to and invade 
host cells. Peptides in sand fly saliva (for example, maxadilan) cause vasodilation and erythema that 
also aids the establishment of the infection in macrophages in the dermal layer of the skin [11]. Early 
responses to infection involve neutrophil infiltration and invasion of resident macrophages. Progress of 
the disease depends on the parasite species and host responses. For both VL and CL, disease progression 
depends on the maintenance of a parasite-specific immunosuppressive state including host cell 
macrophages. A key difference between VL and CL is the propensity of VL-causing species (Table 1) 
to cause disease at systemic sites, invading macrophages of the liver, spleen and bone marrow, with 
minimal skin pathology. Restoration of macrophage function, either through the development of an 
appropriate immune response or therapeutic intervention, can lead to amastigote killing in macrophages 
by nitric oxide and oxygen radicals. Resolution of disease following the activation of macrophages is 
enhanced by T helper 1 (Th1) - like responses mediated through the interaction of antigen-presenting 
cells (e.g., dendritic cells, macrophages) with CD4+ and CD8+ T cells and subsequent secretion of pro-
inflammatory cytokines, including interferon-γ (IFNγ) and tumor necrosis factor (TNF). In clinical 
forms of VL and in DCL, Th2 – like cell responses (including Il-4 and IL-13) are also evident [12,13] 
and inhibition of macrophage activation and immune dysregulation may be mediated through IL-10 and 
transforming growth factor-β (TGFβ) [14].  Immune responses and immunoregulatory pathways have 
been extensively defined in experimental inbred mice that show some but not all the characteristics of 
human disease [15,16].  Immune responses directed against the parasite may also playing a pathogenic 
role and contribute to tissue damage and clinical severity (see below).  
 
The prevention, treatment and control of both CL and VL depends on drugs, diagnostics and vaccines, 
as described in recent comprehensive reviews [2,17]. The complexity and variation of immune 
responses and immunopathology in humans and the different host interactions of the Leishmania 
species has an impact upon the effectiveness of these tools (Fig. 1). Recent studies have significantly 
increased our understanding of these interactions and suggested new strategies for discovery and 
development, and such data are the focus of this review.  
 
2. Key features of immunopathology in leishmaniasis  
Virulence factors allow pathogenic microbes to establish infection, colonise, replicate and disseminate 
throughout the host, evade anti-microbial immunity and facilitate transmission.  A plethora of 
Leishmania derived molecules have been described and reviewed elsewhere that have the cardinal 
properties of bona fide virulence factors [18]. Although some pathogens liberate virulence factors that 
directly cause tissue damage e.g. gangrene due to collagenases and phospholipases produced by 
Clostridium perfringens, similar factors have not yet been described for Leishmania.  Rather, clinical 
symptoms in leishmaniasis are, for the most part, the result of inappropriate immune responses 
leading to collateral damage to host tissues.  Hence, for its clinically relevant features, leishmaniasis 
represents a disease driven by immunopathology.  Hence, the “appropriateness” of an inflammatory / 
immune response, defined by its ability to strike the delicate balance between removal of Leishmania 
parasites and the minimization of pathology, may be defined by its quality, quantity or kinetics as well 
as by the parasite species under study.  Some of the key features of the immunopathology associated 
with leishmaniasis are described below.  
Macrophage activation: Macrophage activation is a central tenet of anti-leishmanial immunity, and 
the capacity of macrophages to polarise their functions towards the generation anti-microbial effector 
molecules such as NO and O2-  under the influence of type 1 cytokines (classical activation) or 
towards the generation of arginine and polyamines under the influence of type 2 cytokines (alternate 
activation) is well established.  However, the simple assumption that type I cytokines are “protective” 
and type 2 cytokines are “detrimental” is not always borne out by the literature.  For example, IL-4, 
the prototypic Th-2 cytokine, plays an important early role in the generation of host protective CD4+ 
IFN+ Th-1 cells in murine models of CL [19] and IL-4R signalling is required for optimal protection 
in primary resistance and vaccine-induced immunity in experimental VL [20-22].   Similarly, 
chemotherapy with sodium stibogluconate (SSG) in models of VL also requires IL-4R signalling for 
optimal effectiveness [22].  More recent evidence indicates that cytokines influence macrophage 
metabolic states, with consequences for the amastigote’s access to required nutrients.  Specific 
metabolic countermeasures may have evolved to combat these stresses and ensure long lived 
parasitism [23].   
Tissue macrophages have two origins. Resident tissue macrophages originate from embryonic yolk 
sac-derived progenitors, fully differentiate to acquire their mature characteristics under the direction 
of tissue-specific transcription factors / tissue-derived cues and have the capacity of self-renewal.  In 
contrast, relatively short-lived tissue macrophages originate from hematopoietic stem cells via 
monocyte precursors [24,25].  Resident tissue macrophages play many of the key roles in tissue 
homeostasis and function, and they have been identified as niches for survival of L. major in the 
dermis [26] and L. donovani in the liver and spleen [27] and it is likely some of their housekeeping 
properties are impacted on by infection.  Monocytes and monocyte-derived macrophages [28-30], as 
well as dendritic cells [31] and neutrophils [32] may also be targets of infection and serve to regulate 
immunity and pathology though their relatively short life span may suggest that there is greater 
dynamics in the parasite populations they contain.  Recent evidence suggests that the bone marrow 
becomes a target of collateral T cell-mediated damage during VL [33,34] but the consequences of this 
for the dynamics of L. donovani infection in these diverse macrophage pools has yet to be fully 
established.  As discussed below, it is also possible that each of these myeloid cell populations will 
have distinct relationships with anti-leishmanial drugs (see section 5), in addition to their roles in 
tissue repair, remodelling and restoration of homeostasis, that are central to the processes 
underpinning clinical cure.  
 
Granulomatous inflammation:  Granulomatous inflammation is a focal mononuclear cell-rich 
response to poorly degradable foreign material that seeks to wall off the insult and /or focus immune 
responses. Granuloma form and function in experimental, canine and human leishmaniasis have been 
reviewed in detail elsewhere [35].  Granulomatous inflammation is a hallmark of VL and correlates 
well in experimental models with the degree of immune response. Failure of granulomatous 
inflammation may contribute to the severity of HIV-VL coinfection [36].  Although over-exuberant, 
granulomatous inflammation may have directly pathologic consequences, e.g. in schistosomiasis, this 
has rarely been described in VL [37].  In TL, granulomas are more variably observed, and may reflect 
the time of biopsy in relation to disease evolution and causative agent.  For example, a recent study in 
Tunisia demonstrated that both granuloma formation and the extent of the dermal lymphocytic 
infiltrate were minimal in L. major zoonotic CL compared to sporadic CL due to L. infantum [38]. 
Granulomas have also been observed in a majority of cases of non-ulcerating atypical CL due to L. 
infantum in Honduras [39] and are a valuable diagnostic characteristic of CL caused by L. donovani in 
Sri Lanka [40].  Although vaccine induced immunity in a primate models of VL was accompanied 
with enhancement of granuloma formation [41], it is not known whether this is a pre-requisite for 
vaccine-induced protection.  In human vaccine trials, histopathological responses to vaccination have 
not been studied to date, and the histopathologic response documented following leishmanisation was 
not documented [42].  The role of granulomatous inflammation in modifying the response to 
chemotherapy (see section 5 below) has not been formally addressed experimentally or clinically, 
largely because appropriate models do not exist and the invasive nature of tissue biopsies.  It is 
possible that the intensity of granulomatous inflammation alters drug PK properties, and that 
macrophages at the core of such structures represent a “privileged” site for amastigotes, but this 
remains to be formally evaluated.   
 
Alterations in tissue architecture: At homeostasis, each tissue has its own characteristic 
microanatomy, dedicated to performing its main function, be that of barrier or as a site of immune 
response induction.  By definition, tissue homeostasis is disrupted during clinical disease and this has 
been most well characterised in the context of remodelling of lymphoid tissue architecture during 
experimental and canine VL.  Immune tissues are highly compartmentalised, with discrete B and T 
cell zones organised on a framework of stromal cells and fed by lymphatics and blood vessels [43]. 
During normal immune responses, these tissues adapt to allow for clonal retention and proliferation, 
but these are usually short-lived changes. Leishmaniasis poses a long-lived insult to lymphoid tissues 
and these respond by exaggerated degree of remodelling that may negatively impact on immune 
function.  In the spleen of mice, dogs and humans infected with L. donovani / L. infantum, these 
changes include loss of stromal elements (follicular dendritic cells and fibroblastic reticular cells), 
dissolution of the marginal zone, white pulp atrophy and various degrees of admixing of splenic 
leucocyte populations [44-46].   
 
Systemic changes in metabolic and immune pathways: Transcriptomics has recently been applied to a 
variety of experimental models and to human samples in order to provide a more holistic view of the 
pathology associated with both VL and CL.  In human VL, comparisons between the whole blood 
transcriptome of healthy endemic controls with active cases, drug-cured cases and asymptomatic 
individuals have been reported from Brazil [47] and India [48].  Transcriptomic analysis of the 
splenic, hepatic and blood response to infection over time has been performed in mice [49] and for 
spleen only in hamsters [50].  High level analysis of these various reports indicates (i) IFN signatures 
are a prominent feature of infection; (ii) Th2 responses are variably represented with a bias to more 
severe disease; iii) changes associated with cell cycle, lipid metabolism, angiogenesis and 
haematological disturbances are evident in active disease and reduced after treatment; iv) treated 
patients, at least over the time period of study, fail to fully return to a homeostatic state.   Not 
surprisingly, each study also identified unique aspects to the transcriptomic profile.   A 
comprehensive cross-organ analysis in the mouse revealed only a limited concordance of DE genes 
between spleen, blood and liver and a clear lack of concordance across species [49].  Although such 
comparative studies require a degree of caution (due to variations in analytical approach), they serve 
as a reminder of the importance of further research on the pathophysiology of human disease.  
 
CL pathogenesis:  In contrast to VL, where studies on pathology have focused on systemic sites, CL 
immunopathology has largely focused on the skin, though many of the changes observed in chronic 
VL lymphoid tissue may also occur in the lymph nodes draining CL lesion sites.  Precise mapping of 
the nature of the inflammatory lesion and its development over time has been reported in murine 
models of CL, most notably due to L. major infection, but also with L. mexicana and L. braziliensis, 
with an emphasis on identifying determinants of host protection (reviewed in [51]) .  More recent 
studies spurred on by clinical observations in human L. braziliensis infection [52] and the 
identification of Leishmania viruses in metastatic strains of L. guyanensis [53] have focused on 
determinants of excessive host pathology.  In L. braziliensis infection, a pathogenic role for CD8+ T 
cells has now been firmly established. At a mechanistic level, highly cytotoxic CD8+ T cells are 
believed to induce the release of cellular DAMPS that trigger inflammasome activation that 
perpetuates the inflammatory cascade. These studies provide opportunities for novel forms of 
immunotherapy to minimise tissue damage [54].  Viral infections are well known as stimulators of the 
type I interferon response and it has been shown that type I interferons either driven by endogenous 
symbiont Leishmania viruses or through concomitant bystander viral infection can lead enhance the 
metastatic potential of L. guyanensis in mouse models [55].  These data require further substantiation 
in a clinical setting, however, but also pose questions regarding novel therapeutic approaches.    
 
3. Vaccines  
The case supporting development of a vaccine for leishmaniasis from a scientific and public health 
perspective has been made many times elsewhere [56].  Vaccine research has included the full range 
of techniques for antigen identification (from the use of serology through to computational prediction, 
[57]) and almost all conceivable vaccine delivery strategies, including cellular vaccination with 
antigen-pulsed dendritic cells, [58,59] have been explored for one or other form of leishmaniasis in 
animal models. Barriers to successful development of a vaccine to date have included i) lack of 
translational funding; ii) lack of correlates of immunity, iii) over-dependence on animal models; and 
iv) lack of a coherent programme of advocacy.  Nevertheless, recent years have seen excellent 
progress that has brought four candidate vaccines to or near to the clinic.  These include a 
recombinant fusion protein delivered with strong Th1-inducing adjuvants (LEISHF3+ GLA-SE; [60]), 
a naked multi-epitope DNA vaccine (LeishDNAvax; [61]), an adenovirus-based vaccine (ChAd63-
KH; [62]) and a live genetically attenuated vaccine (L. major/ L. donovani centrin- [63]).  Each has 
taken a different approach to vaccine antigen identification and vaccine delivery, providing a potential 
rich environment in the future for understanding the determinants of vaccine-induced immunity in 
humans.       
 
Prophylactic vaccines by definition are used in non-infected individuals to prevent the development of 
disease. Hence, immunopathology associated with Leishmania infection does not play a determining 
effect on vaccine design or efficacy. This does not rule out, however, that a subset of the target 
population for vaccination in an endemic setting may harbour sub-clinical and undetectable infections 
(using the diagnostic tools discussed below) that nevertheless have some local pathologic 
consequence.  More likely, however is the scenario whereby co-infections or other intrinsic (e.g. 
nutrition) or extrinsic (e.g. UV radiation) environmental factors impact on vaccine-induced 
lymphocyte activation, memory cell generation and /or effector and regulatory cell balance. Due 
attention should be paid to these possible factors when designing and evaluating future clinical trials. 
In contrast, therapeutic vaccines require enhancement of the state of immunity in those already with 
leishmaniasis pathology.  The extent to which ongoing pathology impacts the efficacy of therapeutic 
vaccines for CL is presently unknown and will require carefully designed clinical trials in which 
patients can be stratified according to pathologic criteria.  In animal models of VL, therapeutic 
vaccination can overcome the immunosuppressive state induced by VL [64] and post-exposure 
prophylactic vaccination in L. infantum-infected dogs was shown to reduce progression to 
symptomatic VL [65].  Prevention of PKDL by vaccination of previously treated VL patients poses an 
interesting challenge,  given that the immune status of treated VL patients is likely to have been 
improved but not normalised [48].  A clinical trial to assess this approach is in development 
(clinicaltrials.gov; NCT04107961).  Combination studies of vaccines deployed with additional 
immunomodulators to overcome pathology-induced immune regulation should be actively considered.  
 
4. Diagnostics  
As the leishmaniases are characterized by their clinical pleomorphism confirmation based solely on 
clinical grounds is a challenge. The wide variety of skin and mucosal lesions in CL involves an 
extensive differential diagnosis. In addition, diseases like malaria, infectious mononucleosis and 
malignancies, among others, present with fever, hepatomegaly and splenomegaly as does VL, often 
accompanied by cachexia and malnutrition in chronic courses.   
Parasite demonstration by microscopy of Giemsa stained tissue smears is the gold standard in the 
diagnosis of leishmaniasis; this is not always accessible and has variable sensitivity. Thus laboratory 
confirmation rates before treating CL can be as low as 5% in some settings, with patients being put on 
treatment with potentially toxic drugs without receiving a confirmatory diagnosis [66]. For VL 
invasive tissue sampling is required, usually from bone marrow or spleen and to a lesser extent lymph 
node. This requires expertise and specialised facilities for managing potential complications, so VL 
suspects are usually referred to specialised treatment centres for diagnosis. Because of this WHO 
recommended that a strict case definition for VL, i.e. fever for more than 2 weeks plus 
hepatosplenomegaly and /or wasting; with this a positive serology enables treatment initiation [67].   
Diagnosis for case management 
A common feature in VL is a polyclonal hypergammaglobulinaemia with a marked increase in serum 
IgG level, including IgG with specificity for Leishmania [68]. Therefore, identifying anti-Leishmania 
specific antibodies is currently the cornerstone of VL diagnosis. Rapid diagnostic tests (RDTs) based 
on the recombinant antigen rK39, from a Leishmania infantum strain from Latin America, are widely 
used and they show very good performance in the Indian subcontinent (ISC): 97% sensitivity (95% 
CI: 90.0 - 99.5), 90.2% specificity (95% CI: 76.1 - 97.7). In eastern Africa the specificity is similar 
91.1% (95% CI: 80.3 - 97.3), but the sensitivity drops to 85.3% (95% CI: 74.5 - 93.2) [69]. This 
inferior performance requires that in eastern Africa it is necessary to include the direct agglutination 
test (DAT) in the diagnostic algorithm (Figure 2). This is a robust test based on whole Leishmania 
antigen and it has been extensively validated. It cannot be considered an RDT as it requires some 
degree of laboratory expertise and capacity, and results are obtained after an overnight incubation 
[70]. 
The peculiarities of the antibody response against specific Leishmania antigens are key in the 
performance of serological tests. VL elicits a different immune response and different levels of anti-
Leishmania IgG across regions. rK39-based RDTs are based on a kinesin sequence from an American 
strain of L. infantum (syn. L. chagasi), this can explain the different performance of these tests in 
eastern Africa, where there is a high molecular diversity of the rK39 homologous sequences among 
regional L. donovani strains [71]. Another explanation for this is that there can be a different potency 
in the immune response, exemplified by the finding that anti-Leishmania IgG levels in VL patients 
from Sudan were significantly lower than in patients from India, independently of the geographic 
origin of the leishmanial antigen used to assess this [72]. A new RDT, based on the recombinant 
antigen rK28, may contribute to overcome this problem. The rK28 is a synthetic polyprotein 
containing rK39 repeats from a Sudanese L. donovani strain, flanked by HASPB1 repeats and the 
HASPB2 open reading frame from an Ethiopian strain [73]. Some preliminary studies claim that rK28 
RDTs show better performance in eastern Africa than those using the rK39 antigen; however, data are 
not definitive, as studies comparing rK28 RDTs with the rK39 RDT IT-Leish (Bio-Rad), which is the 
one recommended in most eastern African guidelines for VL, are limited. These studies are either 
non-prospective or use just serum or plasma from well characterized controls and cases (confirmed by 
parasitology) [74-76]. A prospective large scale evaluation of an rK28 RDT will be conducted by the 
AfriKADIA consortium in Ethiopia, Kenya, Sudan and Uganda; results will be available by the end of 
2020 [https://www.afrikadia.org/].  
Unlike in VL, CL is not characterized by an elevated production of anti-Leishmania antibodies, and 
the level of these is also quite variable between the different forms of tegumentary leishmaniasis. 
Therefore, antibody detection tests are not useful in the diagnosis of these forms of leishmaniasis. 
Anti-Leishmania antibodies are barely detectable in CL and to some extent these can be detected in 
ML and DCL but with limited and variable performance [67]. New opportunities for the serological 
diagnosis of CL may be brought by the detection of anti-α-Gal antibodies, with promising preliminary 
results for Old World leishmaniasis, nevertheless this field requires further research [77]. 
In immunosuppressed HIV+ patients, antibody-detection tests have limited sensitivity and cannot be 
used to rule out VL [78,79]. Also, the detection of total anti-Leishmania antibodies is not very helpful 
in the diagnosis of PKDL or VL relapses, as circulating antibodies from previous VL episodes remain 
for long periods even after successful treatment [80]. It seems however that exploring specific IgG 
types can be of help in assessing post-treatment cure and the risk of relapse, as well as in supporting 
the diagnosis of PKDL. The qualitative and quantitative detection of IgG1 in blood or serum/plasma 
samples, by means of ELISA or RDT using whole or recombinant rK39 leishmanial antigen, have 
shown the potential of IgG1 as a biomarker of post-chemotherapeutic relapse, as demonstrated with 
samples from Sudanese and Indian patients [81-83]. 
Antigen-detection tests can help in resolving some of the problems described above, these tests should 
be more specific and can distinguish active from past infections. Most of the approaches used up to 
date for the detection of leishmanial antigens in VL patients have targeted urine [84-86]. A latex 
agglutination test has shown a highly variable sensitivity (36%-100%) and specificity (64%-99%) 
across endemic regions and different groups of patients, including HIV-positive, thus this has not 
been fully implemented [69]. Different antigen detection ELISA tests have been developed, and they 
have shown high sensitivity and specificity in a preliminary study using samples from VL patients 
from different endemic regions, as well as utility in monitoring treatment efficacy [87]. Lack of 
further evaluation, the need to process the sample and the technical requirements of an ELISA tests 
have precluded putting them into routine practice. A more practical approach would be to detect 
leishmanial antigens in blood or serum/plasma. A prototype immunochromatographic test showed 
high sensitivity (96%) and specificity (99%) in the diagnosis of VL in Chinese patients using blood or 
serum [88]; unfortunately, further validation of this test and its results in other settings has not been 
pursued. 
A point-of-care (POC) tests for early diagnosis of CL is much needed to benefit patients and 
communities, its implementation will reduce morbidity and transmission (where this is 
anthroponotic). A target product profile (TPP) for a POC for CL was developed by consultation 
among experts with a  consensus that this POC test should target Leishmania antigens [89]. A 
promising option for the point-of-care diagnosis of CL that fits this TPP is a RDT detecting the 
leishmanial amastigote antigen peroxidoxin, CL DetectTM Rapid Test (InBios International Inc., 
USA). This test has shown variable performance across endemic regions, but for CL due to L. major 
or L. tropica the sensitivity and specificity obtained in different studies in Tunisia, Morocco and 
Afghanistan is acceptable [90-92]. 
Nucleic acid amplification tests (NAATs) have shown good performance in the diagnosis of the 
different forms of leishmaniasis, both in immunodepressed and immunocompetent patients. 
Polymerase chain reaction (PCR)-based methods have proven that confirmatory diagnosis of VL is 
feasible using a less invasive sample such as peripheral blood, and with high sensitivity  [93]. And 
this is especially relevant in CL, when chronic lesions have lower parasite loads that cannot be 
detected by microscopy [94,95]. A limitation to implement PCR-based diagnosis at the POC has been 
the requirement of well-equipped facilities and trained personnel, as well as the lack of 
standardisation, limiting the use of these tools to reference laboratories. Nevertheless, NAATs more 
amenable for use in limited resource settings have been recently developed, a commercial test based 
on the loop-mediated isothermal amplification (LAMP) of DNA, LoopampTM Leishmania Detection 
Kit (Eiken Chemical Co., Japan), overcomes the problem of standardisation. Its performance using 
peripheral blood (97%-99% sensitivity), as demonstrated in a study in Sudan, enables its inclusion in 
the VL diagnostic algorithm, reducing the need for invasive tissue aspiration [76]. A diagnostics 
evaluation study conducted in Afghanistan informed that an algorithm including CL DetectTM Rapid 
Test and LoopampTM Leishmania Detection Kit would have a sensitivity of 93%, minimizing the 
number of patients that would need to be referred for parasitological confirmation [92]. Other studies 
evaluating non-commercial LAMP assays have also reported high sensitivities in the diagnosis of CL, 
VL and PKDL [96]. As such, the diagnosis and management of leishmaniasis would benefit from the 
implementation of accurate NAATs at the POC. 
Diagnostics in the elimination and post-elimination of visceral leishmaniasis 
WHO aims at eliminating VL as a public health problem in the Indian subcontinent (ISC) by 2020. 
The implementation of test-and-treat strategies, relying on the use of antibody-detection RDTs has 
been pivotal in moving towards this target [97]. This effort will need to be sustained in the next few 
years to avoid resurgence and move towards the interruption of Leishmania transmission by 2030 
[98]. However, the current diagnostic tools may not be adequate to support this endeavour. 
More specific tests will be needed in the near and post-VL elimination phases, since the positive 
predictive value of antibody-detection RDTs decreases in a context of low endemicity [97,99]. Only 
VL suspects with symptoms (e.g. fever, splenomegaly) for more than two weeks are tested by the 
current RDTs, which precludes early diagnosis and treatment of acute cases who remain infectious in 
the community. Reducing the time between onset of symptoms and diagnosis-treatment has been 
identified as a key parameter for achieving and sustaining elimination [100]. But current antibody-
detection RDTs do not allow this, as they are not specific for acute VL and need to be interpreted 
along with a clinical case definition [69]. Detection of Leishmania antigens may be a more specific 
approach [101,102,87,88], and these can be detected earlier than anti-Leishmania antibodies [86,103]. 
Thus antigen-detection RDTs would allow diagnosis of VL cases without a time constraint or clinical 
case definition (e.g. < 2 weeks of fever); as described above several approaches for leishmanial 
antigens detection in clinical samples have been developed, but for different reasons these have not 
been implemented. A recent target product profile describes the features of an antigen detection RDT 
that can be used to assist in VL elimination [104]. Antigen detection tests would also allow 
diagnosing VL in groups of patients in which antibody detection tests underperform such as HIV-VL 
co-infected patients, relapses, as well as in PKDL. All these cases are gaining relevance in the last 
stages of the VL elimination in the ISC, as they are an important reservoir of Leishmania and are a 
serious threat to VL elimination [105,106,99].  
Diagnosis of PKDL is a key factor in elimination efforts as well as in patient management, for PKDL 
treatments are long (up to 12 weeks). PKDL diagnosis is challenging as case confirmation requires 
microscopy and/or molecular tests in skin biopsies. As these diagnostic procedures are difficult to 
perform, diagnosis in endemic areas is often made clinically [107]. Antibody detection RDTs, which 
are part of the PKDL diagnosis algorithm in the ISC, have limited value and alternatives such as 
point-of-care molecular tests with promising performance (e.g. LAMP) should be evaluated [108,99].  
There have been few if any studies directly seeking to evaluate the impact of pathology on the design 
and / or performance of diagnostic tests for VL or CL.  Although there may be limitations in 
translating such knowledge, a consideration of the role of pathology in determining the specificity and 
sensitivity of current and future tests may be warranted. For example, perturbations in the regulation 
of antibody responses are linked to disease progression [109] and antibody and antigen half-lives will 
be affected by changes in plasma or lesion protein binding capacity, glomerular filtration rate (e.g. 
secondary to immune complex deposition [110]) and or the degree of enteropathy [111].  Hence, each 
of the parameters highlighted in Fig. 3 will be influenced by the degree of pathology observed during 
the early pre-clinical, clinical and post-treatment phases of the disease.  As above in the case of 
vaccine efficacy, these pathologic changes might occur directly as a consequence of ongoing or 
previous leishmaniasis, but equally so may reflect the indirect immunopathological consequence of 




There has been considerable progress in the development of treatments for leishmaniasis over the past 
two decades. A number of new drugs have been registered for VL (miltefosine, the liposomal 
formulation AmBisome, paromomycin) with some taking a lead role in disease control and elimination 
programmes [112,2]. At the same time there is an  inadequacy of drugs  for CL [113,114].  However, 
for the first time in history the pipeline of novel oral drugs for the treatment of VL and CL is more 
promising with five novel compounds for VL [115-117] and a renewed focus to find novel treatments 
for CL [118,119]. In this section, two aspects of the drug – immune response interaction will be 
discussed (i) immunosuppression and immunomodulation, and (ii) the impact of immunopathology on 
pharmacokinetics.  
Immunosuppression and immunomodulation 
Interactions between drugs and the immune response have been known, but poorly understood, since 
the early 20th century. It still provides a strong focus for research:  a recent study on antibiotics that 
showed how host cell metabolites both reduce drug activity whilst also enhancing host cell phagocytic 
activity provides an example of such work [120].  For leishmaniasis, as for other infectious diseases, 
there have been two directions of study: (i) to understand why drugs do not work in patients and disease 
models and (ii) the development of a strategy to stimulate/modulate the immune response to overcome 
any immunosuppression or accelerate cure.  
Drugs used for clinical treatment of VL have to work effectively in most endemic regions within the 
context of the immunosuppression provoked by this disease. With the more profound 
immunosuppression associated with HIV VL co-infections, the standard drugs become significantly 
less effective and only co-administrations have been shown to improve treatment [121]. The low 
efficacy of three of the drugs (liposomal amphotericin B, paromomycin and miltefosine) in East African 
VL [122,123]  that are so effective in the Indian subcontinent, has not been explained. Clinical isolates 
from both regions show similar susceptibility to these drugs within standard in vitro assays, so the clear 
implication is that host factors (immunology, pathology, pharmacokinetics [PKs]) are the responsible 
for this difference.  The potential importance of PKs has been illustrated by Dorlo and colleagues [124] 
who have determined different miltefosine exposures in adults and children in East Africa.  There are 
further clinical and experimental observations, one confirming, one confounding: (a) several of the 
drugs that work effectively as VL treatments in immunosuppressed VL patients (ibid) have significant 
dependence on cellular immune responses in mouse models of infection, either immuno-suppressed or 
deficient [125-127], (b)  all the drugs, whether immune or non-immune dependent in these studies, have 
well described interactions with the immune system (see reviews by Dorlo (2012) for miltefosine [128], 
Cohen (2016) for amphotericin B [129] and Murray (2005) for pentavalent antimonials [130]).  It is 
clear that more detailed studies are required to understand these interactions.  
For CL, drugs work within the context of a slow self-cure immune response; exceptions include diffuse 
cutaneous leishmaniasis (DCL) where there is an absence of an effective cellular immune response and 
absence of effective treatment. The objectives for drug treatment, and combinations with 
immunomodulators, are to both reduce the parasite burden and at the same time accelerate self-cure. 
Much of the area lacks clear clinical data due to the absence of robust clinical studies [113,114].   
The central role of the macrophage in the survival of Leishmania parasite has been the driving force 
for most studies on immunomodulation. Have we progressed much further than a statement from 
Bernard Shaw’s play Doctor’s Dilemma (1906) “There is at bottom only one genuinely scientific 
treatment for all diseases, and that is to stimulate the phagocytes” ?  BCG, which has well 
characterised stimulatory interactions with macrophages [131], was the immunodulatory component 
of treatment with pentavalent antimonials and  the recommended treatment for CL in Venezuela 
[132]. It was also used in combination with alum and pentavalent antimonials in clinical trials for the 
treatment of post-kala-azar dermal leishmaniasis [133]. Bacterial cell wall components, muramyl 
dipeptide and trehalose dimycolate have also been used in clinical studies [134] on CL and 
experimental VL [135].  Based on clearer understanding of cytokine-macrophage interaction both 
IFN [136] and GM-CSF [137] have been used in the treatment of both VL and CL. The rationale 
behind the potential application of GM-CSF for CL is threefold: (a) GM-CSF can promote 
proliferation, activation and differentiation of various myeloid cells (macrophages, dendritic cells and 
neutrophils) and their progenitors, (b) clinical trials have reported increased wound healing of diverse 
wound types (including CL) upon topical GM-CSF application, and (iii) CM-CSF is able to modulate 
the tissue immune response by increasing the levels of the anti-inflammatory cytokine IL-10. 
Randomized controlled trials in Brazil have indicated that GM-CSF both after oral [138] and topical 
[139] administration reduced the healing time of CL lesions when given in combination with 
intravenous antimonials.  In addition to its anti-inflammatory role, IL-10 also inhibits IFN induced 
macrophage killing of Leishmania and Murray and colleagues [140] demonstrated in a model of VL 
that blockade of IL-10 using anti-IL-10R antibodies resulted in significant increase in antimonial drug 
activity. A clinical trial to evaluate combining AmBisome with anti-IL-10R antibodies in VL patients 
was proposed but later withdrawn due to unavailability of the required antibody (clinicaltrials.gov; 
NCT01437020).  
Immunomodulator molecules that are also TLR agonists are being pursued for CL treatment. For 
example, CpG-D35, a D-type CpG TLR9 agonist, is currently undergoing Phase-I clinical trials after 
showing it was able to curtail lesion development upon administration to macaque monkeys infected 
with L. major [141]. Earlier studies indicated that this TLR9 agonist induces maturation of plasmacytoid 
dendritic cells and secretion of IFNα and -γ without direct activation of B cells [142]. A  small molecule, 
the imidazoline imiquimod a  TLR7 agonist, was shown  by Matlashewski and colleagues to stimulate 
macrophage functions including signal transduction and  NO production in experimental models, 
sufficient to kill intra-macrophage amastigotes [143]. Subsequent clinical studies using imiquimod as a 
topical adjunct therapy to pentavalent antimonials were inconclusive. Three of these randomized 
controlled trials (RCT) [144-146] showed no significant increased cure rate for the combination of 
imiquimod plus pentavalent antimonials versus antimonials alone. Efforts continue to find more active 
analogues [147].  A different approach was adopted  by Smith et al (2000) with the small molecule, 
tucaresol (in clinical trials for sickle cell disease), an orally bioavailable compound that enhances T-
helper-cell activity, with the induction of increased IL-2 and IFN levels in mice and humans and 
provides a costimulatory signal between macrophages and T-cells [148]. In mouse model of VL 
tucaresol gave a 60% reduction in parasite burden similar to that achieved by INF in the same model.  
Other recent approaches have also added considerably to understanding drug-immune interactions and 
possible new routes forward to immunomodulation and successful cure. Long-term clinical research 
on South American CL [54] showed that NLRP3 inflammasome is activated by CD8+ T cell-mediated 
cytotoxicity and drives disease progression. Based on these observations, the group studied a number 
of small molecule inhibitors of the inflammasome, for example, MCC950 and the diabetes drug 
glyburide.  In mouse models of CL, they showed that mice treatment with compounds that inhibit 
NLRP3 inflammasome activation, MCC950 or glyburide, failed to develop the severe disease seen in 
untreated mice. In VL, more detailed knowledge of the immune response has also been exploited. 
Based on knowledge of the immunopathology of the spleen, the receptor tyrosine kinase inhibitor 
sunitinib maleate was shown to induce restoration of splenic microarchitecture. Although this drug 
did not possess inherent anti-leishmanial activity. it afforded a significant dose sparing effect for 
subsequently administered antimonials [149].  
 
CL is also characterised by local inflammation. A combination of the anti-inflammatory agent, 
pentoxiphylline, with antimonial drugs has been shown to be an important adjunct therapy for some 
forms of CL and mucocutaneous leishmaniasis. In Brazil, randomized controlled trials (RCTs) have 
shown a synergetic effect of pentoxifylline in conjunction to antimonial therapy in ML patients [150] 
whereas this was not observed in patients suffering CL [151,152]. The difference in pentoxifylline 
efficacy as part of a combination therapy between New World CL and ML might be due to distinct 
differences in cytokine and macrophage populations present in the lesion [153] – an observation that 
merits further exploration as it could help elucidate immunomodulatory processes. It is worth noting 
that when tested in Old World CL, the combined approach of pentoxifylline with an antileishmanial 
agend showed enhanced healing in comparison to antileishmanial treatment only [154]. For further 
information on the activity of immunomodulators, see reviews by Dalton and Kaye (2010), Taslimi et 
al., (2018) and Adriaensen et al (2017) [149,155,156].  
PK/PD relationships, immunopathology in drug monitoring and targets for host directed therapy. 
Besides the direct involvement in the disease progression and outcome, the immunopathology also 
impacts drug pharmacodynamics (PD) and/or pharmacokinetics (PK). Impact on the latter has been 
shown in mice with CL, where the presence of parasites and the associated inflammation in the skin 
disturbed the cutaneous barrier function and physiology [157,158]. Interestingly, the permeation of 
hydrophilic compounds increased to a higher extent in comparison to lipophilic compounds which was 
hypothesized to be in part due to the inflammatory hydrophilic environment in CL skin. Whilst these 
findings are particularly important for topical drug administration where the drug is applied locally, 
increased drug levels were also observed in Leishmania-infected skin upon systemic drug 
administration [159,160] where they were associated with enhanced capillary leakiness and increased 
macrophage infiltration both of which could potentially be attributed to local inflammation. How 
Leishmania infection alters the skin tissue microenvironment in humans is yet unknown and is subject 
to further research. 
During the development of VL, the liver, a major drug metabolism site for drugs, undergoes 
morphological and functional changes; hence, it seems evident that VL impacts drug pharmacokinetics. 
In VL infected mice for example, the no-observed-adverse-effect level of miltefosine is approximately 
25 mg/kg (QD, for 10 consecutive days), whereas in experimental CL 35mg/kg is still well tolerated 
(experimental data, unpublished). Other studies also demonstrated a deterioration of the capacity of host 
hepatic microsomal membranes to metabolise xenobiotics in VL infected mice and hamsters [161,162]. 
Whilst in vitro studies suggest no involvement of cytochrome P450 isoenzymes in the metabolism of 
miltefosine [163], the enzymes are involved in the metabolism and clearance of many xenobiotics and 
reduced activity could potentially lead to reduced drug efficacy (metabolites are active) or toxicity when 
increased amounts linger around in the systemic circulation. For amphotericin B, a significantly lower 
concentration of drug was found in liver and spleen of VL-infected mice as compared to uninfected 
mice, which was hypothesised to be due to a reduced phagocytic activity in infected macrophages [155, 
157]. These findings were not investigated in humans but it seems plausible that the PK of certain drugs 
is altered by the disruption of the liver function as observed in VL.  Pathology is also known to affect 
drug ADME (absorption, distribution, metabolism and excretion) processes by alterations in protein 
binding which is important given that hypoalbuminemia is observed in both human and experimental 
VL. Low serum albumin levels have been associated with alterations in the degree of protein binding 
of highly protein-bound drugs such as miltefosine and thus could potentially impact its PK-PD 
relationship [164,165]. 
Another phenomenon which remains unexplored in VL patients and experimental models is the 
influence of granuloma formation on drug PK and thus efficacy. In tuberculosis, a granuloma forms a 
shielded lesion compartment that harbours bacteria and makes it difficult for drugs to permeate [166]; 
hence, the long and intense treatment regimen composed of a cocktail of four different drugs. Whilst 
difference in the extent of granulomatous inflammation are clear between leishmaniasis and TB [35], 
the altered local cellularity of a granuloma may nevertheless be of importance.  
Of further importance is the impact of the pathology on drug PD which involves processes best reflected 
by “what the drug does to the body”. Most chemotherapeutics exert their activity by stimulating or 
inhibiting enzymes that are involved in pathways essential for parasite survival. Recent research 
describes the presence of different metabolically active parasite populations in CL lesions [8]. Kloehn 
et al (2015) measured semi-quiescent L. mexicana parasites in non-healing CL lesions in mice [7]. This 
reduced metabolic state is characterised by low transcription rates and protein turnover and might thus 
contribute to a reduced drug efficacy.  
 
Summary  
Here we have illustrated how the complexity and variation of human immune responses and 
immunopathology and the different host interactions to twenty Leishmania species has an impact 
upon the effectiveness of vaccines, diagnostics and drugs (Fig. 1). Although rodent models have 
proved to be a useful tool for experimental studies on these interactions, well described limitations of 
(a) absence of models for important species (L. aethiopica, L. tropica, L. braziliensis), (b) differences 
between mouse and human immune responses (for example, to TLR agonists, [167,164] and 
serological indicators, and (c) differences in pharmacokinetics between mouse and humans  
[168,165], underpin most of this work. The application of transcriptomics, genomic data bases and 
methodologies to determine pharmacokinetics in infected tissues (not just plasma) in future studies in 
human subjects must now be used to inform future work so tools for treatment, control and 
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Abstract 
 
Leishmaniasis is a disease complex caused by 20 species of protozoan parasites 
belonging to the genus Leishmania. In humans the it has two main clinical forms, 
visceral leishmaniasis (VL) and cutaneous or tegumentary leishmaniasis (CL), as well 
as several other cutaneous manifestations in a minority of cases. In the mammalian 
host Leishmania parasites infect different populations of macrophages where they multiply and 
survive in the phagolysosomal compartment. The progression of both VL and CL 
depends on the maintenance of a parasite-specific immunosuppressive state based 
around this host macrophage infection. The complexity and variation of immune 
responses and immunopathology in humans and the different host interactions of the 
different Leishmania species has an impact upon the effectiveness of vaccines, 
diagnostics and drugs. 
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Leishmaniasis is a disease complex with two main clinical presentations – visceral leishmaniasis (VL, 
or kala-azar) and cutaneous leishmaniasis (CL). Both VL and CL have a worldwide distribution in 
nearly 100 endemic countries. Overall the number of potentially fatal VL cases has decreased during 
the past decade with an estimated annual incidence of less than 50,000 (2017 figures, 
https://www.who.int/leishmaniasis/burden/en accessed 01.10.19) with seven countries: Brazil, 
Ethiopia, India, Kenya, Somalia, South Sudan and Sudan having the major burden. The decrease in VL 
case numbers in the Indian subcontinent (ISC) is coincident with the introduction of a regional 
elimination programme launched in 2005, with improved access to diagnosis and treatment. The 
naturally cyclical pattern of transmission intensity of this anthroponotic disease may also contribute to 
this decrease in the ISC. In contrast, the number of cases in East Africa has not fallen and this endemic 
area is now a major focus for control programmes. The estimated worldwide annual incidence of CL is 
between 0.7 to 1.2 million cases [1] with Central and South America, the Middle East, Ethiopia and 
North Africa being the major endemic areas. Far less attention has been paid to the control and treatment 
of CL, a predominantly zoonotic and a slow self-curing disease (3 – 18 months in most cases) with 
disfigurement and stigma being the main corollaries of infection. In addition, there are rarer variants of 
CL: mucocutaneous leishmaniasis (MCL), diffuse cutaneous leishmaniasis (DCL), disseminated 
cutaneous leishmaniasis (DsCL), leishmaniasis recidivans (LR) and post-kala-azar dermal 
leishmaniasis (PKDL). With CL, these variant skin manifestations are often referred to collectively as 
the tegumentary leishmaniases (TL).  PKDL is a perplexing clinical presentation which follows cure of 
VL (5-10.% cases in Asia, up to 50% cases in East Africa, [2,3]).  
 
The protozoan parasites that cause VL and TL belong to at least 20 distinct species of the genus 
Leishmania (with new species being identified in the past decade) that are transmitted between 
mammalian hosts by female phlebotomine sandflies. Different species of Leishmania are largely 
responsible for the diverse clinical manifestations (Table 1) which are generated by the interplay 
between the parasite, host factors and vector biology. However, clinical cases reports suggest these 
species-dependent clinical outcomes are not distinct.  In the sand fly gut Leishmania parasites exist as 
flagellated promastigote forms, while in the mammalian host the parasites invade macrophages losing 
their flagellum and transforming into to the intracellular amastigote. The amastigote multiplies and 
survives in the phagolysosomal compartment of the macrophage.  It has long been known that 
promastigotes differentiate within the sandfly to generate infective “metacyclic” forms [4-6]  and recent 
evidence suggests that there may also be heterogeneity in the intracellular amastigote form [7-9]. 
Leishmania parasites actively manipulate both of their hosts. In the sandfly, transmission efficiency of 
metacyclic promastigotes is enhanced by secretion of a proteophosphoglycan-rich, mucin-like gel 
(Promastigote Secretory Gel, PSG), which accumulates in the sand fly gut and mouthparts [10].  
Mammalian infection is established in the skin following the inoculation of metacyclic promastigotes 
that possess a lipophosphoglycan coat that enables them to resist complement and attach to and invade 
host cells. Peptides in sand fly saliva (for example, maxadilan) cause vasodilation and erythema that 
also aids the establishment of the infection in macrophages in the dermal layer of the skin [11]. Early 
responses to infection involve neutrophil infiltration and invasion of resident macrophages. Progress of 
the disease depends on the parasite species and host responses. For both VL and CL, disease progression 
depends on the maintenance of a parasite-specific immunosuppressive state including host cell 
macrophages. A key difference between VL and CL is the propensity of VL-causing species (Table 1) 
to cause disease at systemic sites, invading macrophages of the liver, spleen and bone marrow, with 
minimal skin pathology. Restoration of macrophage function, either through the development of an 
appropriate immune response or therapeutic intervention, can lead to amastigote killing in macrophages 
by nitric oxide and oxygen radicals. Resolution of disease following the activation of macrophages is 
enhanced by T helper 1 (Th1) - like responses mediated through the interaction of antigen-presenting 
cells (e.g., dendritic cells, macrophages) with CD4+ and CD8+ T cells and subsequent secretion of pro-
inflammatory cytokines, including interferon-γ (IFNγ) and tumor necrosis factor (TNF). In clinical 
forms of VL and in DCL, Th2 – like cell responses (including Il-4 and IL-13) are also evident [12,13] 
and inhibition of macrophage activation and immune dysregulation may be mediated through IL-10 and 
transforming growth factor-β (TGFβ) [14].  Immune responses and immunoregulatory pathways have 
been extensively defined in experimental inbred mice that show some but not all the characteristics of 
human disease [15,16].  Immune responses directed against the parasite may also playing a pathogenic 
role and contribute to tissue damage and clinical severity (see below).  
 
The prevention, treatment and control of both CL and VL depends on drugs, diagnostics and vaccines, 
as described in recent comprehensive reviews [2,17]. The complexity and variation of immune 
responses and immunopathology in humans and the different host interactions of the Leishmania 
species has an impact upon the effectiveness of these tools (Fig. 1). Recent studies have significantly 
increased our understanding of these interactions and suggested new strategies for discovery and 
development, and such data are the focus of this review.  
 
2. Key features of immunopathology in leishmaniasis  
Virulence factors allow pathogenic microbes to establish infection, colonise, replicate and disseminate 
throughout the host, evade anti-microbial immunity and facilitate transmission.  A plethora of 
Leishmania derived molecules have been described and reviewed elsewhere that have the cardinal 
properties of bona fide virulence factors [18]. Although some pathogens liberate virulence factors that 
directly cause tissue damage e.g. gangrene due to collagenases and phospholipases produced by 
Clostridium perfringens, similar factors have not yet been described for Leishmania.  Rather, clinical 
symptoms in leishmaniasis are, for the most part, the result of inappropriate immune responses 
leading to collateral damage to host tissues.  Hence, for its clinically relevant features, leishmaniasis 
represents a disease driven by immunopathology.  Hence, the “appropriateness” of an inflammatory / 
immune response, defined by its ability to strike the delicate balance between removal of Leishmania 
parasites and the minimization of pathology, may be defined by its quality, quantity or kinetics as well 
as by the parasite species under study.  Some of the key features of the immunopathology associated 
with leishmaniasis are described below.  
Macrophage activation: Macrophage activation is a central tenet of anti-leishmanial immunity, and 
the capacity of macrophages to polarise their functions towards the generation anti-microbial effector 
molecules such as NO and O2-  under the influence of type 1 cytokines (classical activation) or 
towards the generation of arginine and polyamines under the influence of type 2 cytokines (alternate 
activation) is well established.  However, the simple assumption that type I cytokines are “protective” 
and type 2 cytokines are “detrimental” is not always borne out by the literature.  For example, IL-4, 
the prototypic Th-2 cytokine, plays an important early role in the generation of host protective CD4+ 
IFN+ Th-1 cells in murine models of CL [19] and IL-4R signalling is required for optimal protection 
in primary resistance and vaccine-induced immunity in experimental VL [20-22].   Similarly, 
chemotherapy with sodium stibogluconate (SSG) in models of VL also requires IL-4R signalling for 
optimal effectiveness [22].  More recent evidence indicates that cytokines influence macrophage 
metabolic states, with consequences for the amastigote’s access to required nutrients.  Specific 
metabolic countermeasures may have evolved to combat these stresses and ensure long lived 
parasitism [23].   
Tissue macrophages have two origins. Resident tissue macrophages originate from embryonic yolk 
sac-derived progenitors, fully differentiate to acquire their mature characteristics under the direction 
of tissue-specific transcription factors / tissue-derived cues and have the capacity of self-renewal.  In 
contrast, relatively short-lived tissue macrophages originate from hematopoietic stem cells via 
monocyte precursors [24,25].  Resident tissue macrophages play many of the key roles in tissue 
homeostasis and function, and they have been identified as niches for survival of L. major in the 
dermis [26] and L. donovani in the liver and spleen [27] and it is likely some of their housekeeping 
properties are impacted on by infection.  Monocytes and monocyte-derived macrophages [28-30], as 
well as dendritic cells [31] and neutrophils [32] may also be targets of infection and serve to regulate 
immunity and pathology though their relatively short life span may suggest that there is greater 
dynamics in the parasite populations they contain.  Recent evidence suggests that the bone marrow 
becomes a target of collateral T cell-mediated damage during VL [33,34] but the consequences of this 
for the dynamics of L. donovani infection in these diverse macrophage pools has yet to be fully 
established.  As discussed below, it is also possible that each of these myeloid cell populations will 
have distinct relationships with anti-leishmanial drugs (see section 5), in addition to their roles in 
tissue repair, remodelling and restoration of homeostasis, that are central to the processes 
underpinning clinical cure.  
 
Granulomatous inflammation:  Granulomatous inflammation is a focal mononuclear cell-rich 
response to poorly degradable foreign material that seeks to wall off the insult and /or focus immune 
responses. Granuloma form and function in experimental, canine and human leishmaniasis have been 
reviewed in detail elsewhere [35].  Granulomatous inflammation is a hallmark of VL and correlates 
well in experimental models with the degree of immune response. Failure of granulomatous 
inflammation may contribute to the severity of HIV-VL coinfection [36].  Although over-exuberant, 
granulomatous inflammation may have directly pathologic consequences, e.g. in schistosomiasis, this 
has rarely been described in VL [37].  In TL, granulomas are more variably observed, and may reflect 
the time of biopsy in relation to disease evolution and causative agent.  For example, a recent study in 
Tunisia demonstrated that both granuloma formation and the extent of the dermal lymphocytic 
infiltrate were minimal in L. major zoonotic CL compared to sporadic CL due to L. infantum [38]. 
Granulomas have also been observed in a majority of cases of non-ulcerating atypical CL due to L. 
infantum in Honduras [39] and are a valuable diagnostic characteristic of CL caused by L. donovani in 
Sri Lanka [40].  Although vaccine induced immunity in a primate models of VL was accompanied 
with enhancement of granuloma formation [41], it is not known whether this is a pre-requisite for 
vaccine-induced protection.  In human vaccine trials, histopathological responses to vaccination have 
not been studied to date, and the histopathologic response documented following leishmanisation was 
not documented [42].  The role of granulomatous inflammation in modifying the response to 
chemotherapy (see section 5 below) has not been formally addressed experimentally or clinically, 
largely because appropriate models do not exist and the invasive nature of tissue biopsies.  It is 
possible that the intensity of granulomatous inflammation alters drug PK properties, and that 
macrophages at the core of such structures represent a “privileged” site for amastigotes, but this 
remains to be formally evaluated.   
 
Alterations in tissue architecture: At homeostasis, each tissue has its own characteristic 
microanatomy, dedicated to performing its main function, be that of barrier or as a site of immune 
response induction.  By definition, tissue homeostasis is disrupted during clinical disease and this has 
been most well characterised in the context of remodelling of lymphoid tissue architecture during 
experimental and canine VL.  Immune tissues are highly compartmentalised, with discrete B and T 
cell zones organised on a framework of stromal cells and fed by lymphatics and blood vessels [43]. 
During normal immune responses, these tissues adapt to allow for clonal retention and proliferation, 
but these are usually short-lived changes. Leishmaniasis poses a long-lived insult to lymphoid tissues 
and these respond by exaggerated degree of remodelling that may negatively impact on immune 
function.  In the spleen of mice, dogs and humans infected with L. donovani / L. infantum, these 
changes include loss of stromal elements (follicular dendritic cells and fibroblastic reticular cells), 
dissolution of the marginal zone, white pulp atrophy and various degrees of admixing of splenic 
leucocyte populations [44-46].   
 
Systemic changes in metabolic and immune pathways: Transcriptomics has recently been applied to a 
variety of experimental models and to human samples in order to provide a more holistic view of the 
pathology associated with both VL and CL.  In human VL, comparisons between the whole blood 
transcriptome of healthy endemic controls with active cases, drug-cured cases and asymptomatic 
individuals have been reported from Brazil [47] and India [48].  Transcriptomic analysis of the 
splenic, hepatic and blood response to infection over time has been performed in mice [49] and for 
spleen only in hamsters [50].  High level analysis of these various reports indicates (i) IFN signatures 
are a prominent feature of infection; (ii) Th2 responses are variably represented with a bias to more 
severe disease; iii) changes associated with cell cycle, lipid metabolism, angiogenesis and 
haematological disturbances are evident in active disease and reduced after treatment; iv) treated 
patients, at least over the time period of study, fail to fully return to a homeostatic state.   Not 
surprisingly, each study also identified unique aspects to the transcriptomic profile.   A 
comprehensive cross-organ analysis in the mouse revealed only a limited concordance of DE genes 
between spleen, blood and liver and a clear lack of concordance across species [49].  Although such 
comparative studies require a degree of caution (due to variations in analytical approach), they serve 
as a reminder of the importance of further research on the pathophysiology of human disease.  
 
CL pathogenesis:  In contrast to VL, where studies on pathology have focused on systemic sites, CL 
immunopathology has largely focused on the skin, though many of the changes observed in chronic 
VL lymphoid tissue may also occur in the lymph nodes draining CL lesion sites.  Precise mapping of 
the nature of the inflammatory lesion and its development over time has been reported in murine 
models of CL, most notably due to L. major infection, but also with L. mexicana and L. braziliensis, 
with an emphasis on identifying determinants of host protection (reviewed in [51]) .  More recent 
studies spurred on by clinical observations in human L. braziliensis infection [52] and the 
identification of Leishmania viruses in metastatic strains of L. guyanensis [53] have focused on 
determinants of excessive host pathology.  In L. braziliensis infection, a pathogenic role for CD8+ T 
cells has now been firmly established. At a mechanistic level, highly cytotoxic CD8+ T cells are 
believed to induce the release of cellular DAMPS that trigger inflammasome activation that 
perpetuates the inflammatory cascade. These studies provide opportunities for novel forms of 
immunotherapy to minimise tissue damage [54].  Viral infections are well known as stimulators of the 
type I interferon response and it has been shown that type I interferons either driven by endogenous 
symbiont Leishmania viruses or through concomitant bystander viral infection can lead enhance the 
metastatic potential of L. guyanensis in mouse models [55].  These data require further substantiation 
in a clinical setting, however, but also pose questions regarding novel therapeutic approaches.    
 
3. Vaccines  
The case supporting development of a vaccine for leishmaniasis from a scientific and public health 
perspective has been made many times elsewhere [56].  Vaccine research has included the full range 
of techniques for antigen identification (from the use of serology through to computational prediction, 
[57]) and almost all conceivable vaccine delivery strategies, including cellular vaccination with 
antigen-pulsed dendritic cells, [58,59] have been explored for one or other form of leishmaniasis in 
animal models. Barriers to successful development of a vaccine to date have included i) lack of 
translational funding; ii) lack of correlates of immunity, iii) over-dependence on animal models; and 
iv) lack of a coherent programme of advocacy.  Nevertheless, recent years have seen excellent 
progress that has brought four candidate vaccines to or near to the clinic.  These include a 
recombinant fusion protein delivered with strong Th1-inducing adjuvants (LEISHF3+ GLA-SE; [60]), 
a naked multi-epitope DNA vaccine (LeishDNAvax; [61]), an adenovirus-based vaccine (ChAd63-
KH; [62]) and a live genetically attenuated vaccine (L. major/ L. donovani centrin- [63]).  Each has 
taken a different approach to vaccine antigen identification and vaccine delivery, providing a potential 
rich environment in the future for understanding the determinants of vaccine-induced immunity in 
humans.       
 
Prophylactic vaccines by definition are used in non-infected individuals to prevent the development of 
disease. Hence, immunopathology associated with Leishmania infection does not play a determining 
effect on vaccine design or efficacy. This does not rule out, however, that a subset of the target 
population for vaccination in an endemic setting may harbour sub-clinical and undetectable infections 
(using the diagnostic tools discussed below) that nevertheless have some local pathologic 
consequence.  More likely, however is the scenario whereby co-infections or other intrinsic (e.g. 
nutrition) or extrinsic (e.g. UV radiation) environmental factors impact on vaccine-induced 
lymphocyte activation, memory cell generation and /or effector and regulatory cell balance. Due 
attention should be paid to these possible factors when designing and evaluating future clinical trials. 
In contrast, therapeutic vaccines require enhancement of the state of immunity in those already with 
leishmaniasis pathology.  The extent to which ongoing pathology impacts the efficacy of therapeutic 
vaccines for CL is presently unknown and will require carefully designed clinical trials in which 
patients can be stratified according to pathologic criteria.  In animal models of VL, therapeutic 
vaccination can overcome the immunosuppressive state induced by VL [64] and post-exposure 
prophylactic vaccination in L. infantum-infected dogs was shown to reduce progression to 
symptomatic VL [65].  Prevention of PKDL by vaccination of previously treated VL patients poses an 
interesting challenge,  given that the immune status of treated VL patients is likely to have been 
improved but not normalised [48].  A clinical trial to assess this approach is in development 
(clinicaltrials.gov; NCT04107961).  Combination studies of vaccines deployed with additional 
immunomodulators to overcome pathology-induced immune regulation should be actively considered.  
 
4. Diagnostics  
As the leishmaniases are characterized by their clinical pleomorphism confirmation based solely on 
clinical grounds is a challenge. The wide variety of skin and mucosal lesions in CL involves an 
extensive differential diagnosis. In addition, diseases like malaria, infectious mononucleosis and 
malignancies, among others, present with fever, hepatomegaly and splenomegaly as does VL, often 
accompanied by cachexia and malnutrition in chronic courses.   
Parasite demonstration by microscopy of Giemsa stained tissue smears is the gold standard in the 
diagnosis of leishmaniasis; this is not always accessible and has variable sensitivity. Thus laboratory 
confirmation rates before treating CL can be as low as 5% in some settings, with patients being put on 
treatment with potentially toxic drugs without receiving a confirmatory diagnosis [66]. For VL 
invasive tissue sampling is required, usually from bone marrow or spleen and to a lesser extent lymph 
node. This requires expertise and specialised facilities for managing potential complications, so VL 
suspects are usually referred to specialised treatment centres for diagnosis. Because of this WHO 
recommended that a strict case definition for VL, i.e. fever for more than 2 weeks plus 
hepatosplenomegaly and /or wasting; with this a positive serology enables treatment initiation [67].   
Diagnosis for case management 
A common feature in VL is a polyclonal hypergammaglobulinaemia with a marked increase in serum 
IgG level, including IgG with specificity for Leishmania [68]. Therefore, identifying anti-Leishmania 
specific antibodies is currently the cornerstone of VL diagnosis. Rapid diagnostic tests (RDTs) based 
on the recombinant antigen rK39, from a Leishmania infantum strain from Latin America, are widely 
used and they show very good performance in the Indian subcontinent (ISC): 97% sensitivity (95% 
CI: 90.0 - 99.5), 90.2% specificity (95% CI: 76.1 - 97.7). In eastern Africa the specificity is similar 
91.1% (95% CI: 80.3 - 97.3), but the sensitivity drops to 85.3% (95% CI: 74.5 - 93.2) [69]. This 
inferior performance requires that in eastern Africa it is necessary to include the direct agglutination 
test (DAT) in the diagnostic algorithm (Figure 2). This is a robust test based on whole Leishmania 
antigen and it has been extensively validated. It cannot be considered an RDT as it requires some 
degree of laboratory expertise and capacity, and results are obtained after an overnight incubation 
[70]. 
The peculiarities of the antibody response against specific Leishmania antigens are key in the 
performance of serological tests. VL elicits a different immune response and different levels of anti-
Leishmania IgG across regions. rK39-based RDTs are based on a kinesin sequence from an American 
strain of L. infantum (syn. L. chagasi), this can explain the different performance of these tests in 
eastern Africa, where there is a high molecular diversity of the rK39 homologous sequences among 
regional L. donovani strains [71]. Another explanation for this is that there can be a different potency 
in the immune response, exemplified by the finding that anti-Leishmania IgG levels in VL patients 
from Sudan were significantly lower than in patients from India, independently of the geographic 
origin of the leishmanial antigen used to assess this [72]. A new RDT, based on the recombinant 
antigen rK28, may contribute to overcome this problem. The rK28 is a synthetic polyprotein 
containing rK39 repeats from a Sudanese L. donovani strain, flanked by HASPB1 repeats and the 
HASPB2 open reading frame from an Ethiopian strain [73]. Some preliminary studies claim that rK28 
RDTs show better performance in eastern Africa than those using the rK39 antigen; however, data are 
not definitive, as studies comparing rK28 RDTs with the rK39 RDT IT-Leish (Bio-Rad), which is the 
one recommended in most eastern African guidelines for VL, are limited. These studies are either 
non-prospective or use just serum or plasma from well characterized controls and cases (confirmed by 
parasitology) [74-76]. A prospective large scale evaluation of an rK28 RDT will be conducted by the 
AfriKADIA consortium in Ethiopia, Kenya, Sudan and Uganda; results will be available by the end of 
2020 [https://www.afrikadia.org/].  
Unlike in VL, CL is not characterized by an elevated production of anti-Leishmania antibodies, and 
the level of these is also quite variable between the different forms of tegumentary leishmaniasis. 
Therefore, antibody detection tests are not useful in the diagnosis of these forms of leishmaniasis. 
Anti-Leishmania antibodies are barely detectable in CL and to some extent these can be detected in 
ML and DCL but with limited and variable performance [67]. New opportunities for the serological 
diagnosis of CL may be brought by the detection of anti-α-Gal antibodies, with promising preliminary 
results for Old World leishmaniasis, nevertheless this field requires further research [77]. 
In immunosuppressed HIV+ patients, antibody-detection tests have limited sensitivity and cannot be 
used to rule out VL [78,79]. Also, the detection of total anti-Leishmania antibodies is not very helpful 
in the diagnosis of PKDL or VL relapses, as circulating antibodies from previous VL episodes remain 
for long periods even after successful treatment [80]. It seems however that exploring specific IgG 
types can be of help in assessing post-treatment cure and the risk of relapse, as well as in supporting 
the diagnosis of PKDL. The qualitative and quantitative detection of IgG1 in blood or serum/plasma 
samples, by means of ELISA or RDT using whole or recombinant rK39 leishmanial antigen, have 
shown the potential of IgG1 as a biomarker of post-chemotherapeutic relapse, as demonstrated with 
samples from Sudanese and Indian patients [81-83]. 
Antigen-detection tests can help in resolving some of the problems described above, these tests should 
be more specific and can distinguish active from past infections. Most of the approaches used up to 
date for the detection of leishmanial antigens in VL patients have targeted urine [84-86]. A latex 
agglutination test has shown a highly variable sensitivity (36%-100%) and specificity (64%-99%) 
across endemic regions and different groups of patients, including HIV-positive, thus this has not 
been fully implemented [69]. Different antigen detection ELISA tests have been developed, and they 
have shown high sensitivity and specificity in a preliminary study using samples from VL patients 
from different endemic regions, as well as utility in monitoring treatment efficacy [87]. Lack of 
further evaluation, the need to process the sample and the technical requirements of an ELISA tests 
have precluded putting them into routine practice. A more practical approach would be to detect 
leishmanial antigens in blood or serum/plasma. A prototype immunochromatographic test showed 
high sensitivity (96%) and specificity (99%) in the diagnosis of VL in Chinese patients using blood or 
serum [88]; unfortunately, further validation of this test and its results in other settings has not been 
pursued. 
A point-of-care (POC) tests for early diagnosis of CL is much needed to benefit patients and 
communities, its implementation will reduce morbidity and transmission (where this is 
anthroponotic). A target product profile (TPP) for a POC for CL was developed by consultation 
among experts with a  consensus that this POC test should target Leishmania antigens [89]. A 
promising option for the point-of-care diagnosis of CL that fits this TPP is a RDT detecting the 
leishmanial amastigote antigen peroxidoxin, CL DetectTM Rapid Test (InBios International Inc., 
USA). This test has shown variable performance across endemic regions, but for CL due to L. major 
or L. tropica the sensitivity and specificity obtained in different studies in Tunisia, Morocco and 
Afghanistan is acceptable [90-92]. 
Nucleic acid amplification tests (NAATs) have shown good performance in the diagnosis of the 
different forms of leishmaniasis, both in immunodepressed and immunocompetent patients. 
Polymerase chain reaction (PCR)-based methods have proven that confirmatory diagnosis of VL is 
feasible using a less invasive sample such as peripheral blood, and with high sensitivity  [93]. And 
this is especially relevant in CL, when chronic lesions have lower parasite loads that cannot be 
detected by microscopy [94,95]. A limitation to implement PCR-based diagnosis at the POC has been 
the requirement of well-equipped facilities and trained personnel, as well as the lack of 
standardisation, limiting the use of these tools to reference laboratories. Nevertheless, NAATs more 
amenable for use in limited resource settings have been recently developed, a commercial test based 
on the loop-mediated isothermal amplification (LAMP) of DNA, LoopampTM Leishmania Detection 
Kit (Eiken Chemical Co., Japan), overcomes the problem of standardisation. Its performance using 
peripheral blood (97%-99% sensitivity), as demonstrated in a study in Sudan, enables its inclusion in 
the VL diagnostic algorithm, reducing the need for invasive tissue aspiration [76]. A diagnostics 
evaluation study conducted in Afghanistan informed that an algorithm including CL DetectTM Rapid 
Test and LoopampTM Leishmania Detection Kit would have a sensitivity of 93%, minimizing the 
number of patients that would need to be referred for parasitological confirmation [92]. Other studies 
evaluating non-commercial LAMP assays have also reported high sensitivities in the diagnosis of CL, 
VL and PKDL [96]. As such, the diagnosis and management of leishmaniasis would benefit from the 
implementation of accurate NAATs at the POC. 
Diagnostics in the elimination and post-elimination of visceral leishmaniasis 
WHO aims at eliminating VL as a public health problem in the Indian subcontinent (ISC) by 2020. 
The implementation of test-and-treat strategies, relying on the use of antibody-detection RDTs has 
been pivotal in moving towards this target [97]. This effort will need to be sustained in the next few 
years to avoid resurgence and move towards the interruption of Leishmania transmission by 2030 
[98]. However, the current diagnostic tools may not be adequate to support this endeavour. 
More specific tests will be needed in the near and post-VL elimination phases, since the positive 
predictive value of antibody-detection RDTs decreases in a context of low endemicity [97,99]. Only 
VL suspects with symptoms (e.g. fever, splenomegaly) for more than two weeks are tested by the 
current RDTs, which precludes early diagnosis and treatment of acute cases who remain infectious in 
the community. Reducing the time between onset of symptoms and diagnosis-treatment has been 
identified as a key parameter for achieving and sustaining elimination [100]. But current antibody-
detection RDTs do not allow this, as they are not specific for acute VL and need to be interpreted 
along with a clinical case definition [69]. Detection of Leishmania antigens may be a more specific 
approach [101,102,87,88], and these can be detected earlier than anti-Leishmania antibodies [86,103]. 
Thus antigen-detection RDTs would allow diagnosis of VL cases without a time constraint or clinical 
case definition (e.g. < 2 weeks of fever); as described above several approaches for leishmanial 
antigens detection in clinical samples have been developed, but for different reasons these have not 
been implemented. A recent target product profile describes the features of an antigen detection RDT 
that can be used to assist in VL elimination [104]. Antigen detection tests would also allow 
diagnosing VL in groups of patients in which antibody detection tests underperform such as HIV-VL 
co-infected patients, relapses, as well as in PKDL. All these cases are gaining relevance in the last 
stages of the VL elimination in the ISC, as they are an important reservoir of Leishmania and are a 
serious threat to VL elimination [105,106,99].  
Diagnosis of PKDL is a key factor in elimination efforts as well as in patient management, for PKDL 
treatments are long (up to 12 weeks). PKDL diagnosis is challenging as case confirmation requires 
microscopy and/or molecular tests in skin biopsies. As these diagnostic procedures are difficult to 
perform, diagnosis in endemic areas is often made clinically [107]. Antibody detection RDTs, which 
are part of the PKDL diagnosis algorithm in the ISC, have limited value and alternatives such as 
point-of-care molecular tests with promising performance (e.g. LAMP) should be evaluated [108,99].  
There have been few if any studies directly seeking to evaluate the impact of pathology on the design 
and / or performance of diagnostic tests for VL or CL.  Although there may be limitations in 
translating such knowledge, a consideration of the role of pathology in determining the specificity and 
sensitivity of current and future tests may be warranted. For example, perturbations in the regulation 
of antibody responses are linked to disease progression [109] and antibody and antigen half-lives will 
be affected by changes in plasma or lesion protein binding capacity, glomerular filtration rate (e.g. 
secondary to immune complex deposition [110]) and or the degree of enteropathy [111].  Hence, each 
of the parameters highlighted in Fig. 3 will be influenced by the degree of pathology observed during 
the early pre-clinical, clinical and post-treatment phases of the disease.  As above in the case of 
vaccine efficacy, these pathologic changes might occur directly as a consequence of ongoing or 
previous leishmaniasis, but equally so may reflect the indirect immunopathological consequence of 




There has been considerable progress in the development of treatments for leishmaniasis over the past 
two decades. A number of new drugs have been registered for VL (miltefosine, the liposomal 
formulation AmBisome, paromomycin) with some taking a lead role in disease control and elimination 
programmes [112,2]. At the same time there is an  inadequacy of drugs  for CL [113,114].  However, 
for the first time in history the pipeline of novel oral drugs for the treatment of VL and CL is more 
promising with five novel compounds for VL [115-117] and a renewed focus to find novel treatments 
for CL [118,119]. In this section, two aspects of the drug – immune response interaction will be 
discussed (i) immunosuppression and immunomodulation, and (ii) the impact of immunopathology on 
pharmacokinetics.  
Immunosuppression and immunomodulation 
Interactions between drugs and the immune response have been known, but poorly understood, since 
the early 20th century. It still provides a strong focus for research:  a recent study on antibiotics that 
showed how host cell metabolites both reduce drug activity whilst also enhancing host cell phagocytic 
activity provides an example of such work [120].  For leishmaniasis, as for other infectious diseases, 
there have been two directions of study: (i) to understand why drugs do not work in patients and disease 
models and (ii) the development of a strategy to stimulate/modulate the immune response to overcome 
any immunosuppression or accelerate cure.  
Drugs used for clinical treatment of VL have to work effectively in most endemic regions within the 
context of the immunosuppression provoked by this disease. With the more profound 
immunosuppression associated with HIV VL co-infections, the standard drugs become significantly 
less effective and only co-administrations have been shown to improve treatment [121]. The low 
efficacy of three of the drugs (liposomal amphotericin B, paromomycin and miltefosine) in East African 
VL [122,123]  that are so effective in the Indian subcontinent, has not been explained. Clinical isolates 
from both regions show similar susceptibility to these drugs within standard in vitro assays, so the clear 
implication is that host factors (immunology, pathology, pharmacokinetics [PKs]) are the responsible 
for this difference.  The potential importance of PKs has been illustrated by Dorlo and colleagues [124] 
who have determined different miltefosine exposures in adults and children in East Africa.  There are 
further clinical and experimental observations, one confirming, one confounding: (a) several of the 
drugs that work effectively as VL treatments in immunosuppressed VL patients (ibid) have significant 
dependence on cellular immune responses in mouse models of infection, either immuno-suppressed or 
deficient [125-127], (b)  all the drugs, whether immune or non-immune dependent in these studies, have 
well described interactions with the immune system (see reviews by Dorlo (2012) for miltefosine [128], 
Cohen (2016) for amphotericin B [129] and Murray (2005) for pentavalent antimonials [130]).  It is 
clear that more detailed studies are required to understand these interactions.  
For CL, drugs work within the context of a slow self-cure immune response; exceptions include diffuse 
cutaneous leishmaniasis (DCL) where there is an absence of an effective cellular immune response and 
absence of effective treatment. The objectives for drug treatment, and combinations with 
immunomodulators, are to both reduce the parasite burden and at the same time accelerate self-cure. 
Much of the area lacks clear clinical data due to the absence of robust clinical studies [113,114].   
The central role of the macrophage in the survival of Leishmania parasite has been the driving force 
for most studies on immunomodulation. Have we progressed much further than a statement from 
Bernard Shaw’s play Doctor’s Dilemma (1906) “There is at bottom only one genuinely scientific 
treatment for all diseases, and that is to stimulate the phagocytes” ?  BCG, which has well 
characterised stimulatory interactions with macrophages [131], was the immunodulatory component 
of treatment with pentavalent antimonials and  the recommended treatment for CL in Venezuela 
[132]. It was also used in combination with alum and pentavalent antimonials in clinical trials for the 
treatment of post-kala-azar dermal leishmaniasis [133]. Bacterial cell wall components, muramyl 
dipeptide and trehalose dimycolate have also been used in clinical studies [134] on CL and 
experimental VL [135].  Based on clearer understanding of cytokine-macrophage interaction both 
IFN [136] and GM-CSF [137] have been used in the treatment of both VL and CL. The rationale 
behind the potential application of GM-CSF for CL is threefold: (a) GM-CSF can promote 
proliferation, activation and differentiation of various myeloid cells (macrophages, dendritic cells and 
neutrophils) and their progenitors, (b) clinical trials have reported increased wound healing of diverse 
wound types (including CL) upon topical GM-CSF application, and (iii) CM-CSF is able to modulate 
the tissue immune response by increasing the levels of the anti-inflammatory cytokine IL-10. 
Randomized controlled trials in Brazil have indicated that GM-CSF both after oral [138] and topical 
[139] administration reduced the healing time of CL lesions when given in combination with 
intravenous antimonials.  In addition to its anti-inflammatory role, IL-10 also inhibits IFN induced 
macrophage killing of Leishmania and Murray and colleagues [140] demonstrated in a model of VL 
that blockade of IL-10 using anti-IL-10R antibodies resulted in significant increase in antimonial drug 
activity. A clinical trial to evaluate combining AmBisome with anti-IL-10R antibodies in VL patients 
was proposed but later withdrawn due to unavailability of the required antibody (clinicaltrials.gov; 
NCT01437020).  
Immunomodulator molecules that are also TLR agonists are being pursued for CL treatment. For 
example, CpG-D35, a D-type CpG TLR9 agonist, is currently undergoing Phase-I clinical trials after 
showing it was able to curtail lesion development upon administration to macaque monkeys infected 
with L. major [141]. Earlier studies indicated that this TLR9 agonist induces maturation of plasmacytoid 
dendritic cells and secretion of IFNα and -γ without direct activation of B cells [142]. A  small molecule, 
the imidazoline imiquimod a  TLR7 agonist, was shown  by Matlashewski and colleagues to stimulate 
macrophage functions including signal transduction and  NO production in experimental models, 
sufficient to kill intra-macrophage amastigotes [143]. Subsequent clinical studies using imiquimod as a 
topical adjunct therapy to pentavalent antimonials were inconclusive. Three of these randomized 
controlled trials (RCT) [144-146] showed no significant increased cure rate for the combination of 
imiquimod plus pentavalent antimonials versus antimonials alone. Efforts continue to find more active 
analogues [147].  A different approach was adopted  by Smith et al (2000) with the small molecule, 
tucaresol (in clinical trials for sickle cell disease), an orally bioavailable compound that enhances T-
helper-cell activity, with the induction of increased IL-2 and IFN levels in mice and humans and 
provides a costimulatory signal between macrophages and T-cells [148]. In mouse model of VL 
tucaresol gave a 60% reduction in parasite burden similar to that achieved by INF in the same model.  
Other recent approaches have also added considerably to understanding drug-immune interactions and 
possible new routes forward to immunomodulation and successful cure. Long-term clinical research 
on South American CL [54] showed that NLRP3 inflammasome is activated by CD8+ T cell-mediated 
cytotoxicity and drives disease progression. Based on these observations, the group studied a number 
of small molecule inhibitors of the inflammasome, for example, MCC950 and the diabetes drug 
glyburide.  In mouse models of CL, they showed that mice treatment with compounds that inhibit 
NLRP3 inflammasome activation, MCC950 or glyburide, failed to develop the severe disease seen in 
untreated mice. In VL, more detailed knowledge of the immune response has also been exploited. 
Based on knowledge of the immunopathology of the spleen, the receptor tyrosine kinase inhibitor 
sunitinib maleate was shown to induce restoration of splenic microarchitecture. Although this drug 
did not possess inherent anti-leishmanial activity. it afforded a significant dose sparing effect for 
subsequently administered antimonials [149].  
 
CL is also characterised by local inflammation. A combination of the anti-inflammatory agent, 
pentoxiphylline, with antimonial drugs has been shown to be an important adjunct therapy for some 
forms of CL and mucocutaneous leishmaniasis. In Brazil, randomized controlled trials (RCTs) have 
shown a synergetic effect of pentoxifylline in conjunction to antimonial therapy in ML patients [150] 
whereas this was not observed in patients suffering CL [151,152]. The difference in pentoxifylline 
efficacy as part of a combination therapy between New World CL and ML might be due to distinct 
differences in cytokine and macrophage populations present in the lesion [153] – an observation that 
merits further exploration as it could help elucidate immunomodulatory processes. It is worth noting 
that when tested in Old World CL, the combined approach of pentoxifylline with an antileishmanial 
agend showed enhanced healing in comparison to antileishmanial treatment only [154]. For further 
information on the activity of immunomodulators, see reviews by Dalton and Kaye (2010), Taslimi et 
al., (2018) and Adriaensen et al (2017) [149,155,156].  
PK/PD relationships, immunopathology in drug monitoring and targets for host directed therapy. 
Besides the direct involvement in the disease progression and outcome, the immunopathology also 
impacts drug pharmacodynamics (PD) and/or pharmacokinetics (PK). Impact on the latter has been 
shown in mice with CL, where the presence of parasites and the associated inflammation in the skin 
disturbed the cutaneous barrier function and physiology [157,158]. Interestingly, the permeation of 
hydrophilic compounds increased to a higher extent in comparison to lipophilic compounds which was 
hypothesized to be in part due to the inflammatory hydrophilic environment in CL skin. Whilst these 
findings are particularly important for topical drug administration where the drug is applied locally, 
increased drug levels were also observed in Leishmania-infected skin upon systemic drug 
administration [159,160] where they were associated with enhanced capillary leakiness and increased 
macrophage infiltration both of which could potentially be attributed to local inflammation. How 
Leishmania infection alters the skin tissue microenvironment in humans is yet unknown and is subject 
to further research. 
During the development of VL, the liver, a major drug metabolism site for drugs, undergoes 
morphological and functional changes; hence, it seems evident that VL impacts drug pharmacokinetics. 
In VL infected mice for example, the no-observed-adverse-effect level of miltefosine is approximately 
25 mg/kg (QD, for 10 consecutive days), whereas in experimental CL 35mg/kg is still well tolerated 
(experimental data, unpublished). Other studies also demonstrated a deterioration of the capacity of host 
hepatic microsomal membranes to metabolise xenobiotics in VL infected mice and hamsters [161,162]. 
Whilst in vitro studies suggest no involvement of cytochrome P450 isoenzymes in the metabolism of 
miltefosine [163], the enzymes are involved in the metabolism and clearance of many xenobiotics and 
reduced activity could potentially lead to reduced drug efficacy (metabolites are active) or toxicity when 
increased amounts linger around in the systemic circulation. For amphotericin B, a significantly lower 
concentration of drug was found in liver and spleen of VL-infected mice as compared to uninfected 
mice, which was hypothesised to be due to a reduced phagocytic activity in infected macrophages [155, 
157]. These findings were not investigated in humans but it seems plausible that the PK of certain drugs 
is altered by the disruption of the liver function as observed in VL.  Pathology is also known to affect 
drug ADME (absorption, distribution, metabolism and excretion) processes by alterations in protein 
binding which is important given that hypoalbuminemia is observed in both human and experimental 
VL. Low serum albumin levels have been associated with alterations in the degree of protein binding 
of highly protein-bound drugs such as miltefosine and thus could potentially impact its PK-PD 
relationship [164,165]. 
Another phenomenon which remains unexplored in VL patients and experimental models is the 
influence of granuloma formation on drug PK and thus efficacy. In tuberculosis, a granuloma forms a 
shielded lesion compartment that harbours bacteria and makes it difficult for drugs to permeate [166]; 
hence, the long and intense treatment regimen composed of a cocktail of four different drugs. Whilst 
difference in the extent of granulomatous inflammation are clear between leishmaniasis and TB [35], 
the altered local cellularity of a granuloma may nevertheless be of importance.  
Of further importance is the impact of the pathology on drug PD which involves processes best reflected 
by “what the drug does to the body”. Most chemotherapeutics exert their activity by stimulating or 
inhibiting enzymes that are involved in pathways essential for parasite survival. Recent research 
describes the presence of different metabolically active parasite populations in CL lesions [8]. Kloehn 
et al (2015) measured semi-quiescent L. mexicana parasites in non-healing CL lesions in mice [7]. This 
reduced metabolic state is characterised by low transcription rates and protein turnover and might thus 
contribute to a reduced drug efficacy.  
 
Summary  
Here we have illustrated how the complexity and variation of human immune responses and 
immunopathology and the different host interactions to twenty Leishmania species has an impact 
upon the effectiveness of vaccines, diagnostics and drugs (Fig. 1). Although rodent models have 
proved to be a useful tool for experimental studies on these interactions, well described limitations of 
(a) absence of models for important species (L. aethiopica, L. tropica, L. braziliensis), (b) differences 
between mouse and human immune responses (for example, to TLR agonists, [167,164] and 
serological indicators, and (c) differences in pharmacokinetics between mouse and humans  
[168,165], underpin most of this work. The application of transcriptomics, genomic data bases and 
methodologies to determine pharmacokinetics in infected tissues (not just plasma) in future studies in 
human subjects must now be used to inform future work so tools for treatment, control and 
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 Main Reservoir Countries or regions found 
L. donovani VL, PKDL Fatal within two years (VL). PKDL lesions 
may follow drug treatment 
Humans 
India, Bangladesh, Ethiopia, Sudan, 
South Sudan 
L. tropica CL, LR, rarely VL Self-healing within 12-18 months Humans 
East Mediterranean, Middle East, 
North Africa 
L. aethiopica CL, DCL, DsCL  Self-healing (except DCL) within 2-5 years. Hyraxes Ethiopia, Kenya 
L. major CL Self-healing within 3-12 months. Rodents 
North Africa, Middle East, Central 
Asia, West Africa 
L. infantum  
[L. chagasi]  
VL, CL 
Can be fatal within two years (VL), most 
adults asymptomatic 
Dogs, humans 
China, South Europe, Brazil, 
South and Central America 
L. braziliensis CL, MCL, DCL, LR 
May self-heal within six months. 
















VL= Visceral Leishmaniasis; PKDL = Post-Kala-Azar Dermal Leishmaniasis; CL = Cutaneous Leishmaniasis; MCL = Mucocutaneous Leishmaniasis; DCL = Diffuse 






















Fever ≥ 2 weeks with splenomegaly or wasting 
(rule out malaria)
Previous VL case
Perform tissue aspirate microscopy
(lymph node/ bone marrow/spleen)
Negative
Search for other 
diagnosis and treat 
or refer
Positive
VL treatment as 
relapse
NEW case*











Re-test in 1 





Search for other 





VL diagnostic algorithm. Source: National guidelines from Ethiopia, Kenya, Sudan and Uganda
* Parasitological diagnosis may also be conducted in tertiary hospitals and research centres























Key facets of leishmaniasis pathology 
Figure 1
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We thank the reviewer for comment and corrections.  We have:  
Added 5 new references in the immunology/vaccine sections which refer to the DC issues 
raised by the reviewer.  Our aim was not to produce a full review on all aspects on immune 
regulation but to focus on issues indicated in the title of the manuscript. 
We have added an additional paragraph on molecular diagnostics with an additional 5 
references; this does add to the manuscript.  
Apologies that the Table 1 was omitted from the first submission. This was the corresponding 
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